Vitamin K Antagonists, Non-Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation.

1 . Regression analyses, adjusted for the propensity scores to correct for the identified confounders, revealed that patients in the VKA treatment group had significantly more AsAC and DAC when compared with the non-anticoagulation group (AsAC: odds ratio [OR] 2.31, 95% confidence interval [CI] 1.16–4.59, p = 0.017; DAC: OR 2.38, 95% CI 1.22–4.67, p = 0.012) and showed a trend toward a higher calcium score of the aortic valve (AVC: OR 1.92, 95% CI 0.98–3.80, p = 0.059; Fig. 2A ).

also in 53,322 other papers